Clasp Therapeutics, a biotechnology company pioneering precision immuno-oncology through next-generation T cell engagers (TCEs), has announced its official launch this month, backed by $150 million in Series A financing. Clasp seeks to address the unmet needs of cancer patients who do not respond to existing treatments.

Clasp Therapeutics是一家通过下一代T细胞参与者（TCE）开创精准免疫肿瘤学的生物技术公司，该公司已于本月宣布正式推出，并获得了1.5亿美元的a系列融资支持。Clasp旨在解决对现有治疗无反应的癌症患者未满足的需求。

The firm is backed by Third Rock Ventures, Novo Holdings, and Catalio Capital; with participation from Vivo Capital, Cure Ventures, Blackbird BioVentures, Pictet Alternative Advisors, American Cancer Society's Bright Edge and Alexandria Venture Investments..

该公司由第三摇滚风险投资公司（Third Rock Ventures）、Novo Holdings和Catalio Capital提供支持；维梧资本、Cure Ventures、Blackbird BioVentures、Pictet Alternative Advisors、美国癌症协会Bright Edge和亚历山大风险投资公司的参与。。